How do I install the Endo Avoid Preop Medical Therapy skill?

Run npx skillmds@latest add dromlakhani/endo-avoid-preop-medical-therapy in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Avoid Preop Medical Therapy safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Avoid Preop Medical Therapy?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Avoid Preop Medical Therapy free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Avoid Preop Medical Therapy?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Avoid Preop Medical Therapy by dromlakhani

Name: Endo Avoid Preop Medical Therapy
Rating: 4.5 (4 reviews)
Author: dromlakhani

Endo Avoid Preop Medical Therapy

The guideline recommends against routine preoperative medical therapy (e.g., somatostatin receptor ligands) solely to improve postoperative biochemical control in acromegaly. Consider this when planning transsphenoidal surgery and evaluating whether to initiate medical pretreatment.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Avoid routine preoperative medical therapy to improve biochemical control

STEP 1 — Gather Information

Confirm biochemical diagnosis of acromegaly (elevated IGF-1, lack of GH suppression after oral glucose load)
Document planned transsphenoidal surgery
Assess for severe pharyngeal thickness, sleep apnea, or high‑output heart failure
Record baseline IGF‑1 and GH levels, tumor size, and parasellar extent on MRI Action: Proceed to evaluate indications for preoperative SRL.

STEP 2 — Rule In / Rule Out

Rule in: Presence of severe pharyngeal thickness, sleep apnea, or high‑output heart failure → indicates preoperative SRL may be used to reduce surgical risk (not for biochemical control)
Rule out: Absence of these features → routine preoperative medical therapy not indicated for improving postoperative biochemical control
Decision: If ruled in, go to Step 3; if ruled out, go to Step 4.

STEP 3 — Classify or Stratify

Classify patient as needing preoperative SRL for risk reduction (e.g., to mitigate airway or cardiac complications)
Select appropriate SRL agent and dose (e.g., octreotide LAR 20 mg monthly or lanreotide autogel 90 mg monthly) to be started preoperatively and continued per standard regimen
Action: Initiate preoperative SRL for risk reduction; do not aim for biochemical control.

STEP 4 — Decide

Decide against routine preoperative medical therapy solely to improve postoperative biochemical control
Proceed with transsphenoidal surgery without preoperative SRL; plan postoperative IGF‑1 measurement at 12 weeks to assess remission
Action: Withhold preoperative SRL for biochemical control; proceed to surgery.

Clinical Guardrails / Mimics / Pitfalls

Do not use preoperative SRL solely to normalize IGF‑1 before surgery; no proven benefit in postoperative remission rates and may confound early postoperative testing.
Avoid delaying surgery for prolonged preoperative medical therapy aiming for biochemical control.
Preoperative SRL may reduce tumor size and improve surgical safety in high‑risk patients (severe sleep apnea, pharyngeal thickening, high‑output heart failure) but this is for risk mitigation, not biochemical control.
Pitfall: Misinterpreting early postoperative IGF‑1 suppression due to carryover effect of preoperative SRL as surgical remission; wait ≥12 weeks post‑op and consider washout if needed.

Concrete Clinical Example

A 45‑year‑old with acromegaly (IGF‑1 +2× ULN, nonsuppressed GH) is evaluated for transsphenoidal surgery. He reports mild snoring but has no documented severe pharyngeal thickening, sleep apnea, or high‑output heart failure. Routine preoperative octreotide is not recommended solely to improve postoperative biochemical control. Surgery proceeds without preoperative medical therapy; IGF‑1 is measured at 12 weeks post‑op to assess remission.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2700

---name: endo-avoid-preop-medical-therapydescription: The guideline recommends against routine preoperative medical therapy (e.g., somatostatin receptor ligands) solely to improve postoperative biochemical control in acromegaly. Consider this when planning transsphenoidal surgery and evaluating whether to initiate medical pretreatment.---# Avoid routine preoperative medical therapy to improve biochemical control## STEP 1 — Gather Information- Confirm biochemical diagnosis of acromegaly (elevated IGF-1, lack of GH suppression after oral glucose load)- Document planned transsphenoidal surgery- Assess for severe pharyngeal thickness, sleep apnea, or high‑output heart failure- Record baseline IGF‑1 and GH levels, tumor size, and parasellar extent on MRI**Action:** Proceed to evaluate indications for preoperative SRL.## STEP 2 — Rule In / Rule Out- **Rule in:** Presence of severe pharyngeal thickness, sleep apnea, or high‑output heart failure → indicates preoperative SRL may be used to reduce surgical risk (not for biochemical control) - **Rule out:** Absence of these features → routine preoperative medical therapy not indicated for improving postoperative biochemical control **Decision:** If ruled in, go to Step 3; if ruled out, go to Step 4.## STEP 3 — Classify or Stratify- Classify patient as needing preoperative SRL for **risk reduction** (e.g., to mitigate airway or cardiac complications) - Select appropriate SRL agent and dose (e.g., octreotide LAR 20 mg monthly or lanreotide autogel 90 mg monthly) to be started preoperatively and continued per standard regimen **Action:** Initiate preoperative SRL for risk reduction; do not aim for biochemical control.## STEP 4 — Decide- Decide **against** routine preoperative medical therapy solely to improve postoperative biochemical control - Proceed with transsphenoidal surgery without preoperative SRL; plan postoperative IGF‑1 measurement at 12 weeks to assess remission **Action:** Withhold preoperative SRL for biochemical control; proceed to surgery.## Clinical Guardrails / Mimics / Pitfalls- Do not use preoperative SRL solely to normalize IGF‑1 before surgery; no proven benefit in postoperative remission rates and may confound early postoperative testing. - Avoid delaying surgery for prolonged preoperative medical therapy aiming for biochemical control. - Preoperative SRL may reduce tumor size and improve surgical safety in high‑risk patients (severe sleep apnea, pharyngeal thickening, high‑output heart failure) but this is for risk mitigation, not biochemical control. - Pitfall: Misinterpreting early postoperative IGF‑1 suppression due to carryover effect of preoperative SRL as surgical remission; wait ≥12 weeks post‑op and consider washout if needed.## Concrete Clinical ExampleA 45‑year‑old with acromegaly (IGF‑1 +2× ULN, nonsuppressed GH) is evaluated for transsphenoidal surgery. He reports mild snoring but has no documented severe pharyngeal thickening, sleep apnea, or high‑output heart failure. Routine preoperative octreotide is **not** recommended solely to improve postoperative biochemical control. Surgery proceeds without preoperative medical therapy; IGF‑1 is measured at 12 weeks post‑op to assess remission.**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2700

Frequently asked questions